<DOC>
	<DOCNO>NCT02003651</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness ingest alkylamide-rich echinacea root product ( Quick Defense , Gaia Herbs ) 2 day immediately follow onset acute respiratory illness ( ARI ) symptomatology 12-week period winter early spring woman . Hypothesis : Subjects randomize Quick Defense compare placebo 12-week period experience reduce ARI symptomatology , acutely ARI episode collectively entire 12-week study period .</brief_summary>
	<brief_title>Echinacea Acute Respiratory Illness</brief_title>
	<detailed_description>The common cold acute respiratory illness ( ARI ) frequent illness people experience , economic cost estimate $ 40 billion per year ( Ann Intern Med 2010 ; 153:769-777 ) . Hundreds different type virus cause common cold , etiologic agent include rhinovirus , coronavirus , influenza , parainfluenza , respiratory syncytial virus , adenovirus , enterovirus , metapneumovirus . The purple coneflower ( E. angustifolia E. purpurea ) one popular herbal supplement North America Europe . Echinacea preparation market provide protection treatment common cold . Reviews meta-analyses provide modest support use Echinacea prevention treatment common cold ( Can Fam Physician 2011 ; 57:31-6 ; Cochrane Database Syst Rev 2006 Jan 25 ; ( 1 ) : CD000530 ; Lancet Infect Dis 2007 ; 7:473-80 ; Clin Ther . 2006 Feb ; 28 ( 2 ) :174-83 ) . One meta-analysis conclude echinacea decrease odds develop common cold 58 % duration cold 1.4 day ( Lancet Infect Dis 2007 ; 7:473-80 ) . Echinacea product vary composition , due use different specie , plant part , extraction method , addition component ( Planta Med 2008 ; 74:633-7 ) . Some preparation base stabilize fresh juice aerial part E. purpurea , rich hydrophilic derivative polysaccharide glycoprotein . Other echinacea product come extract root material contain lipophilic compound include N-alkylamides ( Ann Intern Med 2010 ; 153:769-777 ) . Studies indicate echinacea preparation contain N-alkylamides bioavailable human suppress stress-related cellular immune response ( Life Sci 2009 ; 85 ( 3-4 ) :97-106 ) . Echinacea preparation contain N-alkylamides link multiple immune-modulatory activity include enhanced macrophage phagocytic activity suppression proinflammatory responses epithelial cell virus bacteria ( J Biomed Biotechnol . 2012 ; 2012:769896 ) . Echinacea preparation appear low potential generate cytochrome P450 ( CYP 450 ) drug-herb interaction , verifiable report drug-herb interaction . The estimate risk take echinacea product 1 100,000 , thus appear pose risk consumer ( Mol Nutr Food Res . 2008 ; 52 ( 7 ) :789-98 ) . Barrett et al . ( Ann Intern Med 2010 ; 153:769-777 ) enrol subject within 36 hour illness onset , administer echinacea tablet ( placebo ) contain 675 mg E. purpurea root standardize 2.1 mg alkamides 600 mg E. angustifolia root standardize 2.1 mg alkamides . Subjects consume two tablet enrollment , follow two-tablet dos three time within 24 hour enrollment . Dosing go one tablet four time daily next four day . Thus , participant ingest equivalent 10.2 g dry echinacea root first 24 hour equivalent 5.1g next four day . Results direction benefit , amount average half day reduction duration week-long cold , approximate 10 % reduction overall severity . The propose study build upon study Barrett et al. , ( 2010 ) initiate 2-day use alkylamide-rich echinacea root product ( Quick Defense , Gaia Herbs ) within first hour ARI onset throughout 12-week period winter/early spring . 1 . DESIGN GUIDELINES : 1 . Following recruitment , subject come ASU-NCRC Human Performance Lab ( visit 1 pre-study visit ) orientation provide voluntary consent join study . All subject inclusion exclusion criterion must maintain study . 2 . Subjects fill medical health questionnaire verify medical history lifestyle habit ( complete hand visit 1 ) . 3 . Subjects two additional laboratory visit ( 6-weeks 12-weeks ) ASU-NCRC Human Performance Laboratory . At three lab visit , body weight percent body fat ( Tanita BIA scale ) measure . Height measure pre-study visit . At lab visit , subject also record responses 6-week retrospective symptom log . At pre-study 6-week study visit , subject give 6-week daily log book , Wisconsin Upper Respiratory Symptom Survey ( WURSS-24 ) , assess symptom related common cold . Subjects turn 6-week 12-week visit . Subjects fill 6-week retrospective WURSS-24 visit 1 . Subjects interview lab staff week 6 12 determine whether change medical history medication use . 4 . Subjects ( N=40-46 ) randomize Quick Defense placebo group 12 week ( thus two independent group 20-23 subject ) . Supplements administer double-blinded manner , code hold Gaia Herbs end study . 2 . SUPPLEMENT : Echinacea ( Quick Defense ) identical placebo capsule manufacture Gaia Herbs ( Brevard , NC ) . Gaia Herbs conduct analysis product verify supplement content . Two echinacea capsule contain equivalent 250 mg E. purpurea root 83 mg E.angustifolia root standardize 10 mg alkylamides , 210 mg proprietary synergistic extract blend contain andrographis paniculata leaf , black elderberry berry , sambucus nigra , ginger root , zingiber officinale ( see label ) . Capsule excipients include vegetable glycerin olive oil , capsule contain vegetable cellulose . Placebo echinacea capsule color green contain proportion inert ingredient . DOSING REGIMEN : During 12-week study , subject take 2 capsule 5 time daily ( approximately every 3 hour ) 2 day time feel symptom acute respiratory illness ( ARI ) start . Thus subject ingest equivalent 3.4 gram dry echinacea root first two day ARI onset . No additional echinacea ( placebo ) capsule take first two day illness onset next ARI episode experience . c. COMMON COLD SYMPTOMS : The Wisconsin Upper Respiratory Symptom Survey ( WURSS-24 ) use assess common cold illness severity symptom ( see attach questionnaire ) . Scores WURSS-24 include : 1 ) Global severity score ; 2 ) Symptom score ; 3 ) Function ability score ( Barrett et al. , 2009 ) . The WURSS-24 ( short version use study ) include 10 item assess symptom ( run nose , plug nose , sneeze , sore throat , scratchy throat , cough , hoarseness , head congestion , chest congestion , feel tire ) , 9 item assess functional impairment ( think clearly , sleep well , breathe easily , walk-climb stairs-exercise , accomplish daily activity , work outside home , work inside home , interact others , live personal life ) , 1 item assess global severity global change . Subjects fill one-page WURSS-24 end day 12-week monitoring period . This 12-week period cover winter early spring period 2014 . From response record 84-day study , ARI severity score calculate sum daily ARI global severity score ( 0=not sick , 1=very mild ARI 7=severe ) . The ARI symptom score 84-day period calculate sum 10 symptom score day 's entry ( 0=do symptom , 1=very mild 7=severe ) . In similar fashion , ARI function ability score 84-day period calculate sum 9 function score day 's entry ( 0=do symptom , 1=very mild 7=severe ) . Separate score calculate compare group illness episode record subject .</detailed_description>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Adult woman , age 18 55 year . Nonsmokers . Willingness avoid use antibiotic , antiviral , nasal steroid , decongestant , antihistamine , combination cold formula , echinacea , zinc , vitamin C 12week study . Willingness maintain normal dietary physical activity pattern 12week intervention , make formal attempt lose body weight . Current history autoimmune immune deficiency disease . History moderate severe allergic rhinitis sneeze itch nose eye winter/early spring . Current history asthma coughing , wheeze , shortness breath . Pregnant planning pregnant study . History gastrointestinal upset , rash , allergic reaction Echinacea .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Common cold</keyword>
</DOC>